HCP Efficacy Information
HCP Efficacy Information - YONDELIS®
YONDELIS is the first FDA-approved treatment for liposarcoma and leiomyosarcoma studied against an active comparator in a phase 3 trial.
Efficacy - NUWIQ® Official HCP Website
Clinical evidence proves patients achieved effective bleeding control with NUWIQ® [Antihemophilic Factor (Recombinant)]. Please see important safety info.
Healthcare Professionals (HCPs) are typically familiar with the importance of clinical trials, the gold standard for evaluating the safety and efficacy of new ...
Healthcare Effectiveness Data and Information Set (HEDIS)
The Healthcare Effectiveness Data and Information Set (HEDIS) is a tool used by more than 90 percent of U.S. health plans to measure performance on ...
Efficacy Data for KEYTRUDA® (pembrolizumab) | Clinical Trial Results
Browse the indications approved for treatment with KEYTRUDA® (pembrolizumab). Open to review efficacy and safety information, and you will also find links to ...
TRD Efficacy & Safety | SPRAVATO® (esketamine) HCP
View SPRAVATO® efficacy data and study results in adult patients with TRD, including safety considerations. See full Prescribing & Safety Info, ...
The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials.
The DLP for this interim analysis was on the date when participants had completed at least 4 additional years of follow-up, and data accrual was complete ...
Efficacy & Safety Data | OGSIVEO® (nirogacestat) HCP Site
OGSIVEO significantly improved progression-free survival · Median PFS in the OGSIVEO arm was not reached (95% CI: NR, NR) compared with 15.1 months (95% CI: 8.4 ...
Efficacy data | UBRELVY® (ubrogepant) | HCP
DEMONSTRATED DATA FOR TREATMENT EARLY IN THE MIGRAINE ATTACK ... 46% of patients avoided moderate to severe headache pain within 24 hours postdose with UBRELVY.
Efficacy in Clinical Trials | TAKHZYRO® (lanadelumab-flyo)
Subgroup results from the 300 mg Q4W arm of the HELP study · 80% reduction in attacks on average vs placebo for patients who had 1 to <2 HAE attacks per month at ...
The majority of patients achieved blood Phe levels ≤360 μmol/L and most achieved this Phe level with the recommended dosing schedule.
APRETUDE (cabotegravir 200 mg/mL) Efficacy | HCP Website
Explore efficacy data, the study design and baseline characteristics for the HPTN 083 & 084 APRETUDE (cabotegravir 200 mg/mL) studies. For US HCPs only.
YESCARTA® (axicabtagene ciloleucel) Efficacy Information | HCP
YESCARTA delivers durable, complete remissions. 1 Compelling response rates in Cohorts 1 and 2: pivotal and 2-year analyses.
Data from patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing.
1 - Proven Efficacy: Phase III CORRECT Data | Stivarga US HCP
1 - Proven Efficacy: Phase III CORRECT Data · Proven Efficacy: Phase III CORRECT Data · Proven Efficacy: Phase III CORRECT Data · What strategies are available ...
Efficacy Data, Study Design & Clinical Trials - Kisunla - Eli Lilly
Find efficacy data, clinical data ... The information contained in kisunla.lilly.com/hcp is intended for healthcare professionals in the United States only.
KYMRIAH® (tisagenlecleucel) Efficacy Data & Clinical Trials | HCP
About 8/10 patients achieved minimal residual disease negative (MRD-negative) remission at 3 months after treatment with KYMRIAH (tisagenlecleucel).
COLUMVI™ (glofitamab-gxbm) efficacy | HCP
Durable remissions achieved with fixed-duration therapy · Long-term follow-up data: Duration of Response and Complete Response · Indication · BOXED WARNING.
Efficacy Information | OPDIVO® (nivolumab)
Efficacy data across a broad range of patients ... Please verify that you are a U.S. Healthcare Professional. This information is intended for U.S. Healthcare ...